Autoimmune diseases are the third most common disease influencing the quality of life of many patients. Here, a programmed cell death‐ligand 1 + (PD‐L1) mesenchymal stem cell (MSC) derived extracellular vesicles (MSC‐sEVs‐PD‐L1) using lentivirus‐mediated gene transfection technology is developed for reconfiguration of the local immune microenvironment of affected tissue in autoimmune diseases. MSC‐sEVs‐PD‐L1 exhibits an impressive ability to regulate various activated immune cells to an immunosuppressed state in vitro. More importantly, in dextran sulfate sodium‐induced ulcerative colitis (UC) and imiquimod‐induced psoriasis mouse models, a significantly high accumulation of MSC‐sEVs‐PD‐L1 is observed in the inflamed tissues compared to the PD‐L1+ MSCs. Therapeutic efficiency in both UC and psoriasis mouse disease models is demonstrated using MSC‐sEVs‐PD‐L1 to reshape the inflammatory ecosystem in the local immune context. A technology is developed using MSC‐sEVs‐PD‐L1 as a natural delivery platform for autoimmune diseases treatment with high clinical potential.